OC
ATYR

Oppenheimer & Co’s aTyr Pharma ATYR Stock Holding History

Oppenheimer & Co’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,343
Closed -$81K – 1356
2020
Q2 		$81K Sell
18,343
-598
-3% -$2.17K ﹤0.01% 1215
2020
Q1 		$53K Buy
+18,941
New +$81.8K ﹤0.01% 1156

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Oppenheimer & Co's ATYR Position: Q3 2020 in Review

Oppenheimer & Co sold out of aTyr Pharma (ATYR) in Q3 2020, closing a stake of 18,343 shares — an estimated $81K sold.

Oppenheimer & Co first reported a position in ATYR in Q1 2020 and held it in 2 quarters. The position peaked at $81K in Q2 2020. 25 funds tracked by Wall St. Rank hold ATYR as of Q3 2020.

  • Oppenheimer & Co reported no remaining aTyr Pharma position as of Q3 2020 after selling out during the quarter.
  • Oppenheimer & Co sold 18,343 aTyr Pharma shares in Q3 2020, an estimated $81K.
  • Oppenheimer & Co first reported a position in aTyr Pharma in Q1 2020 and held it in 2 quarters.
  • Oppenheimer & Co's aTyr Pharma position peaked at $81K in Q2 2020.
  • 25 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2020.

Based on Oppenheimer & Co's 13F filing for Q3 2020, filed 13 Nov 2020.